Periinterventional Coagulation Management of Patients Undergoing a TIPS
Key facts
- Who runs it
- Medical University of Graz
- Where
- Austria1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 39 people, planned
- Started
- 27 May 2020
- Expected to end
- May 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- thrombelastogram
- standard of care
- Record updated
- 13 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Liver cirrhosis
- >18 years
- Indication for TIPS implantation
- Ability to sign informed consent exclusion criteria
- Contraindications against TIPS implantation
- Hepatocellular carcinoma BCLC D
- Ongoing bleeding
- pre-existing anticoagulant therapy at time of inclusion
- administration of blood products within 1 week prior to the enrolment
- Other malignancies that lead to an impaired 90-day survival
- Inherit blood clotting disorders
- Hepatic encephalopathy grade 3 or 4
- any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Assess whether a pre-interventional thrombelastography guided algorithm for assessing and correction of coagulation status in cirrhotic patients is safe and effective
The 2 groups in the trial
- Thrombelastogram (TEG)Treatment being tested
Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm.
Treatment: thrombelastogram
- Standard of Care (SOC)Treatment being tested
In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR\>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
Treatment: standard of care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Optimizing Periinterventional Coagulation Management of Patients Undergoing a Transjugular Intrahepatic Portosystemic Shunt Implantation: A Prospective Randomized Cohort Study
- Record updated
- 13 October 2026